AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28544581
Drug: MPH XR‐ODT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPH XR‐ODT and Reference medication
Trial: 7992348
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg albendazole
Trial: 7992348
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg mebendazole
Trial: 11145488
Drug: Rivastigmine (6-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine (6-12 mg daily)
Trial: 31594738
Drug: Behavioral intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral intervention to promote CC screening
Trial: 26588006
Drug: Electronic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic medication dispenser (EMD) used for 1 year
Trial: 26588006
Drug: Electronic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic medication dispenser (EMD)
Trial: 19690954
Drug: H ‐‐>
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: H ‐‐> H + D (trastuzumab monotherapy followed by trastuzumab plus docetaxel)
Trial: 18555937
Drug: G-ER BID
RxNorm normalized name: quinidine gluconate Extended Release Oral Tablet [Quin-G]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-ER BID (600 mg at 8 am and 1200 mg at 8 pm)
Trial: 18555937
Drug: G-IR TID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-IR TID (600 mg at 8 am, 2 pm, and 8 pm)
Trial: 11907659
Drug: Constant inflation
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant inflation flow (CF) at 0.40 l/s
Trial: 11907659
Drug: Decelerating inflation
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decelerating inflation flow (DF) at 0.70 l/s
Trial: 11907659
Drug: Decelerating inflation
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decelerating inflation flow (DF) at 1.10 l/s
Trial: 6849209
Drug: Metronidazole +
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole + Gentamicin (M + G)
Trial: 6849209
Drug: Clindamycin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin + Gentamicin (C + G)
Trial: 28161147
Drug: Ranibizumab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (0.5 mg/0.05 ml)
Trial: 27814737
Drug: Placebo (lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose monohydrate, daily for 3 months)
Trial: 24443804
Drug: Intra-articular hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular hyaluronic acid (IA-HA) injection once a week for five weeks
Trial: 24443804
Drug: Oral non-steroidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral non-steroidal anti-inflammatory drugs (NSAIDs) three times per day for five weeks
Trial: 24443804
Drug: Intra-articular hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular hyaluronic acid (IA-HA) injection
Trial: 795608
Drug: Three drug
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three drug schemes including 1 tablet t.d.s. (three times daily)
Trial: 21685187
Drug: Candidate SNPs
RxNorm normalized name: SNP-ACTH (1-39)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candidate SNPs within cholinergic receptors, nicotinic, alpha 3/5 (CHRNA3/CHRNA5)
Trial: 19297141
Drug: Prednisolone 40mg
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 40mg once daily for 2 weeks
Trial: 10487800
Drug: Lovastatin (33
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (33 mg/day)
Trial: 1691811
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed by radiotherapy (arm A)
Trial: 2451713
Drug: Alternating chemotherapy
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating chemotherapy and radiotherapy (arm B)
Trial: 25649967
Drug: Advice meeting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advice meeting Institute of Medicine recommendations
Trial: 21922138
Drug: 520 mg
RxNorm normalized name: aspirin 520 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 520 mg of ferrous sulfate once a day
Trial: 17591659
Drug: Ketamine 0.27
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.27 mg/kg
Trial: 17591659
Drug: Ketamine 0.081
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.081 mg/kg
Trial: 16671337
Drug: Benazepril (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril (10-20 mg/day) or Imidapril (5-10 mg/day) for 6 weeks
Trial: 12200950
Drug: Spinal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal block with bupivacaine 0.5% hyperbaric solution 10 mg (n = 20)
Trial: 7634515
Drug: Gentamicin 4
RxNorm normalized name: gentamicin 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 4 mg/kg q24h iv
Trial: 7634515
Drug: Netilmicin 5.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netilmicin 5.5 mg/kg q24h iv
Trial: 31100353
Drug: Primary IOL
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary IOL treatment in unilaterally affected eyes (pre-IATS)
Trial: 31100353
Drug: Primary IOL
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary IOL treatment in unilaterally affected eyes (post-IATS)
Trial: 31100353
Drug: Primary IOL
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary IOL treatment in bilaterally affected eyes (pre-IATS)
Trial: 31100353
Drug: Primary IOL
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary IOL treatment in bilaterally affected eyes (post-IATS)
Trial: 31100353
Drug: Year-wise calculation
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Year-wise calculation of primary IOL treatment
Trial: 25638526
Drug: Mean doses
RxNorm normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean doses to BOT, OC, and VP
Trial: 22348833
Drug: 3-day omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-day omeprazole administration
Trial: 22348833
Drug: 3-day famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-day famotidine administration
Trial: 29774169
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg daily
Trial: 19687332
Drug: Everolimus 70
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus 70 mg weekly
Trial: 17606174
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal medicine trials
Trial: 17606174
Drug: Conventional medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medicine trials
Trial: 12779186
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy plus education
Trial: 28239984
Drug: Extended-release naltrexone
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release naltrexone (XR‐NTX) for 78 weeks
Trial: 26521574
Drug: Conventional rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional rehabilitation training and medication (Control group).
Trial: 9934936
Drug: Half-cycle sertraline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-cycle sertraline dosing
Trial: 9934936
Drug: Full-cycle sertraline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-cycle sertraline dosing
Trial: 7776527
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine 1.5 mg.kg‐1 2 minutes before laryngoscopy
Trial: 7776527
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl 4 micrograms.kg‐1
Trial: 2157364
Drug: Cisplatin, vindesine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin, vindesine and mitomycin combination regimen
Trial: 74352
Drug: (+)-cyanidanol-3 (1.5g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (+)-cyanidanol-3 (1.5g daily)
Trial: 26120075
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (1 g daily for 5 days)
Trial: 23890767
Drug: Viscum album
RxNorm normalized name: Viscum album
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viscum album [L.] extract (VaL) therapy
Trial: 23890767
Drug: Viscum album
RxNorm normalized name: Viscum album
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viscum album [L.] extract (VaL) therapy in 'good' prognosis subgroup
Trial: 23890767
Drug: No antineoplastic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antineoplastic therapy (control) in 'poor' prognosis subgroup
Trial: 12407061
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (group 3)
Trial: 3816876
Drug: Once-a-day dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-a-day dosing (15 mg metaclazepam in the evening)
Trial: 3816876
Drug: Twice-a-day dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-a-day dosing (5 mg in the morning plus 10 mg in the evening)
Trial: 26691837
Drug: Trastuzumab (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (6 mg/kg, single intravenous infusion over 90 min)
Trial: 21813569
Drug: Transfer into
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transfer into an open cot at 1600 g
Trial: 6323087
Drug: Ranitidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (50 mg intravenous injection)
Trial: 6323087
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg oral dosing)
Trial: 6323087
Drug: Ranitidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (0.5 microgram/ml serum concentration)
Trial: 30604091
Drug: Lilly insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lilly insulin glargine (LY IGlar)
Trial: 21490024
Drug: Oral oxycodone
RxNorm normalized name: oxycodone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oxycodone (OOXY)
Trial: 16766975
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy (VAC) for hematomas
Trial: 11134474
Drug: Adderall (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adderall (0.15 mg/kg/dose and 0.3 mg/kg/dose)
Trial: 31640452
Drug: Office-based placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Office-based placebo therapy (OBPT)
Trial: 26602318
Drug: Blueberry treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blueberry treatment (300g of blueberries) + smoking (one cigarette)
Trial: 25263326
Drug: Smoking treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking treatment (one cigarette)
Trial: 20542854
Drug: Telephone administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telephone administration of outcome measures
Trial: 18447217
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Yueyueshu Decoction
Trial: 15805349
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy at 67 microg/kg per day
Trial: 15805349
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy at 33 microg/kg per day
Trial: 12412977
Drug: BDP-HFA (beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP-HFA (beclomethasone dipropionate aerosol spray 500 microg b.i.d. via Jet spacer)
Trial: 3378514
Drug: Atenolol 50mg
RxNorm normalized name: ATENOLOL 50MG TAB
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol 50mg twice daily
Trial: 26501499
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment (N = 33)
Trial: 19716278
Drug: LABA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LABA treatment
Trial: 7669477
Drug: 2% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lignocaine 3.5 ml
Trial: 2257867
Drug: SCR 4
RxNorm normalized name: Sildenafil citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCR 4 mg
Trial: 2257867
Drug: SCR 8
RxNorm normalized name: Scopolamine
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SCR 8 mg
Trial: 2257867
Drug: SCR 4
RxNorm normalized name: Sildenafil citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCR 4 mg and SCR 8 mg
Trial: 36117
Drug: Lorazepam 2-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 2-2.5 mg
Trial: 3287911
Drug: Piroxicam 40
RxNorm normalized name: piroxicam 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 40 mg once daily for two days, then 20 mg daily for five days
Trial: 3287911
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg twice daily for five days
Trial: 17002709
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (200 mcg once daily for 4 weeks)
Trial: 15284344
Drug: Placebo (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (50 ml saline)
Trial: 9113184
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine 1.25 micrograms/kg
Trial: 2868812
Drug: Intracoronary propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary propranolol (1.1 +/- 0.2 mg)
Trial: 2868812
Drug: Intracoronary placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary placebo (saline, 2 ml)
Trial: 8602564
Drug: Verapamil retard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil retard 360 mg/day
Trial: 1707230
Drug: Low-dose Adriamycin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Adriamycin (doxorubicin, 20 mg/m2) alone
Trial: 1707230
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with bleomycin and vincristine (ABV)
Trial: 18408049
Drug: Nebulised furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulised furosemide 40 mg
Trial: 8000815
Drug: 15% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% glucose solution (1 g kg‐1 body mass)
Trial: 3291901
Drug: Continuous-course treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous-course treatment (212 patients)
Trial: 20961748
Drug: Sham ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham ultrasound therapy
Trial: 27027660
Drug: Single-session psychoeducation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-session psychoeducation treatment
Trial: 21939626
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline infusion (HHS) 2 ml/kg (7.2% NaCl with 6% hydroxyethyl starch) over 10 min
Trial: 21939626
Drug: HES infusion
RxNorm normalized name: HE-2200
DrugBank: HE-2200 (DB06257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES infusion over 10 min
Trial: 20831698
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg b.i.d.
Trial: 10651664
Drug: OAC (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC (omeprazole 20 mg b.d., amoxycillin 1 g b.d., clarithromycin 500 mg b.d.)
Trial: 10215733
Drug: Second-line therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line therapy (quadruple regimen: omeprazole 20 mg b.d., tripotassium dicitrato bismuthate 120 mg q.d.s., tetracycline 500 mg q.d.s., metronidazole 400 mg t.d.s.)
Trial: 10215733
Drug: Second-line therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line therapy (2-week proton pump inhibitor-based triple therapy)
Trial: 10215733
Drug: Second-line therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line therapy (1-week proton pump inhibitor-based triple therapy)
Trial: 25496052
Drug: Interactive balance
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive balance training program (4 weeks, twice a week) with wearable sensors providing visual/auditory feedback
Trial: 17709294
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (BoNT-A) treatment
Trial: 10361663
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg intrathecal morphine sulfate
Trial: 10361663
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg intrathecal morphine sulfate
Trial: 10361663
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg intrathecal morphine sulfate
Trial: 7572762
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin plus penicillin V (group A)
Trial: 3093827
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg at night)
Trial: 27714506
Drug: Intermittent balneological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent balneological treatment for 5 weeks (10 sessions of hydrotherapy and mud pack therapy)
Trial: 15825711
Drug: FGF 2
RxNorm normalized name: FGF 2
DrugBank: Basic Fibroblast Growth Factor (DB14131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FGF 2 l.min(‐1)
Trial: 15825711
Drug: FGF 1
RxNorm normalized name: Fibroblast Growth Factor 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FGF 1 l.min(‐1)
Trial: 9613912
Drug: Nebulized budesonide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized budesonide, 2 mg
Trial: 3516755
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg sodium diclofenac tablet (Novapirina) every 12 hours for 2 consecutive days
Trial: 3516755
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg tablet of acetylsalicylic acid (Aspirin) every 8 hours for 2 consecutive days
Trial: 22357185
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (IG)
Trial: 29502065
Drug: Tracheal intubation
RxNorm normalized name: bovine type II collagen (tracheal cartilage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tracheal intubation with 1.5 mg/kg propofol and 1 µg/kg remifentanil, followed by 0.9 mg/kg rocuronium
Trial: 15659242
Drug: Rivastigmine high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine high-dose therapy
Trial: 12516679
Drug: Braun Oral‐B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Braun Oral‐B 3D Excel (PTB1)
Trial: 12516679
Drug: Increased toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased toothbrush force from 90 g to 150 g
Trial: 2102705
Drug: 4-carbomethoxythiazolidine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-carbomethoxythiazolidine 400 mg/d
Trial: 2102705
Drug: 4-carbomethoxythiazolidine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-carbomethoxythiazolidine 600 mg/d
Trial: 2102705
Drug: 4-carbomethoxythiazolidine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-carbomethoxythiazolidine 200 mg/d (three times a day)
Trial: 21788433
Drug: Unshorn sheep
RxNorm normalized name: sheep wool preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unshorn sheep (treatment group)
Trial: 21788433
Drug: Post-shearing (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-shearing (treatment group)